Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Disease stages and therapeutic hypotheses in two decades of neurodegenerative disease clinical trials

Meredith A. Mortberg, View ORCID ProfileSonia M. Vallabh, View ORCID ProfileEric Vallabh Minikel
doi: https://doi.org/10.1101/2022.06.16.22276513
Meredith A. Mortberg
1McCance Center for Brain Health and Department of Neurology, Massachusetts General Hospital, Boston, MA, 02114
2Stanley Center for Psychiatric Research, Broad Institute, Cambridge, MA 02142
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sonia M. Vallabh
1McCance Center for Brain Health and Department of Neurology, Massachusetts General Hospital, Boston, MA, 02114
2Stanley Center for Psychiatric Research, Broad Institute, Cambridge, MA 02142
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sonia M. Vallabh
Eric Vallabh Minikel
1McCance Center for Brain Health and Department of Neurology, Massachusetts General Hospital, Boston, MA, 02114
2Stanley Center for Psychiatric Research, Broad Institute, Cambridge, MA 02142
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Eric Vallabh Minikel
  • For correspondence: eminikel@broadinstitute.org
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Structured Abstract

Background Neurodegenerative disease is increasing in prevalence and remains without disease-modifying therapies, and most trials of new drugs fail. Proposed solutions include aiming upstream: targeting molecular root causes of disease and testing therapies earlier, even at pre-symptomatic stages. We sought to understand what disease stages were eligible to enroll in neurodegenerative disease clinical trials in recent years and what molecular targets were tested in these trials.

Methods We combined automated analysis and manual curation of trial registrations from ClinicalTrials.gov for Alzheimer’s disease, Parkinson’s disease, frontotemporal dementia / amyotrophic lateral sclerosis, and Huntington’s disease.

Findings 3,241 trials from 2000-2020 were curated. Industry-sponsored drug trials, a minority (34%) of trials but a majority (61%) of patient-years, were more likely to complete, to have specified phase, and to have placebo or standard-of-care control arms. The mean number of inclusion and exclusion criteria more than doubled over this period, and eligible score ranges shrank. Trials have shifted towards less severely impaired participants, but only 2.7% of trials were open to pre-symptomatic individuals and these were depleted for industry sponsors (OR = 0.32) and for drug trials (OR = 0.59), instead being enriched for behavioral interventions (OR = 3.1). 16 novel, genetically supported therapeutic hypotheses have been tested in drug trials, with a mean lag of 13 years from genetic association to first trial. Such trials comprised just 18% of patient-years.

Interpretation Eligibility criteria for trials have shifted towards earlier, milder disease stages but are still overwhelmingly focused on symptomatic patients, particularly for industry-sponsored drug trials. Drugs targeting disease genes supported by human genetics comprise a small fraction of drug development effort, and their success may be hindered by a focus on symptomatic patients.

Competing Interest Statement

MAM reports no disclosures. SMV has received speaking fees from Ultragenyx, Illumina, and Biogen, consulting fees from Invitae, and research support in the form of unrestricted charitable contributions from Ionis, Gate, and Charles River. EVM has received consulting fees from Deerfield and research support in the form of unrestricted charitable contributions from Ionis, Gate, and Charles River.

Funding Statement

This work was supported by the National Institutes of Health (R21 TR003040 and R01 NS125255). The funder had no role in study design, analysis, interpretation, or decision to publish.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Additional panels in Figure 4, broader review of prior literature in introduction.

Data Availability

All data and source code used in this study will be made publicly available at http://github.com/ericminikel/nd_trials and are sufficient to reproduce the figures and statistics herein.

https://github.com/ericminikel/nd_trials

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted June 21, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Disease stages and therapeutic hypotheses in two decades of neurodegenerative disease clinical trials
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Disease stages and therapeutic hypotheses in two decades of neurodegenerative disease clinical trials
Meredith A. Mortberg, Sonia M. Vallabh, Eric Vallabh Minikel
medRxiv 2022.06.16.22276513; doi: https://doi.org/10.1101/2022.06.16.22276513
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Disease stages and therapeutic hypotheses in two decades of neurodegenerative disease clinical trials
Meredith A. Mortberg, Sonia M. Vallabh, Eric Vallabh Minikel
medRxiv 2022.06.16.22276513; doi: https://doi.org/10.1101/2022.06.16.22276513

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Neurology
Subject Areas
All Articles
  • Addiction Medicine (227)
  • Allergy and Immunology (500)
  • Anesthesia (110)
  • Cardiovascular Medicine (1230)
  • Dentistry and Oral Medicine (205)
  • Dermatology (147)
  • Emergency Medicine (282)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (529)
  • Epidemiology (10005)
  • Forensic Medicine (5)
  • Gastroenterology (497)
  • Genetic and Genomic Medicine (2445)
  • Geriatric Medicine (236)
  • Health Economics (479)
  • Health Informatics (1635)
  • Health Policy (751)
  • Health Systems and Quality Improvement (633)
  • Hematology (248)
  • HIV/AIDS (531)
  • Infectious Diseases (except HIV/AIDS) (11855)
  • Intensive Care and Critical Care Medicine (625)
  • Medical Education (251)
  • Medical Ethics (74)
  • Nephrology (267)
  • Neurology (2273)
  • Nursing (139)
  • Nutrition (349)
  • Obstetrics and Gynecology (452)
  • Occupational and Environmental Health (532)
  • Oncology (1244)
  • Ophthalmology (375)
  • Orthopedics (133)
  • Otolaryngology (226)
  • Pain Medicine (154)
  • Palliative Medicine (50)
  • Pathology (324)
  • Pediatrics (729)
  • Pharmacology and Therapeutics (311)
  • Primary Care Research (282)
  • Psychiatry and Clinical Psychology (2280)
  • Public and Global Health (4824)
  • Radiology and Imaging (833)
  • Rehabilitation Medicine and Physical Therapy (488)
  • Respiratory Medicine (650)
  • Rheumatology (283)
  • Sexual and Reproductive Health (237)
  • Sports Medicine (225)
  • Surgery (266)
  • Toxicology (44)
  • Transplantation (124)
  • Urology (99)